Stock fact sheet · data as of
Biodexa Pharmaceuticals Plc (BDRX): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United Kingdom · ADR · Speculative / Distressed
Is BDRX undervalued?
BDRX has a margin of safety of 100%: the stock closed at 0.4314 on 16 Oct 2026 against a GLS average fair value of 515.53. 1 of the 1 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files BDRX under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for BDRX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 515.53 | +119403% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 7.58 | +1658% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: BDRX passes 1 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -54.6%, ROE -54.8%, ROA -34.4% - with debt at 0.01 times equity and negative free cash flow.
Biodexa Pharmaceuticals Plc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -54.6% |
|---|---|---|---|
| GLS Moat | 1.5 / 10 | ROE | -54.8% |
| Debt / equity | 0.01 | ROA | -34.4% |
| Free-cash-flow yield | -2874.1% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 39: No options
BDRX has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 1.6M shares a day on a market cap of $322K, with a beta of 1.28 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 13 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 100% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 2 / 15 | moat 1.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 13 / 20 | 1.6M shares/day, $0M cap, beta 1.28 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for BDRX in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Biodexa Pharmaceuticals Plc by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| LYRA Lyra Therapeutics, Inc. | 0.1900 | - | - | 28No options | $337K |
| BCTXZ BriaCell Therapeutics Corp. Warrant | 0.1565 | 19.13 | +99% | 37No options | $295K |
| HCWB HCW Biologics Inc. | 1.23 | - | - | 22No options | $428K |
| CDT CDT Equity Inc. | 0.2090 | 5,315.64 | +100% | 39No options | $235K |
| SCNI Scinai Immunotherapeutics Ltd. | 0.8800 | 98.61 | +99% | 39No options | $455K |
| AMPE Ampio Pharmaceuticals, Inc. | 0.1831 | 4.89 | +96% | 33No options | $208K |
| NIKI Niki BioSolutions, Inc. | 2.22 | 0.1355 | -1538% | 10No options | $181K |
| PPBT Purple Biotech Ltd. | 1.23 | 1.39 | +12% | 34Weak | $170K |
| DCOY Decoy Therapeutics Inc. | 1.23 | 20.43 | +94% | 37No options | $654K |
| HXBM Helix BioMedix, Inc. | 3.29 | - | - | 22No options | $739K |
| PPCB Propanc Biopharma, Inc. | 0.3657 | 0.2233 | -64% | 13No options | $833K |
| CRIS Curis, Inc. | 0.5080 | - | - | 20No options | $991K |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BDRX
Is BDRX undervalued right now?
By the GLS models, yes: at 0.4314 the stock is 100% below the average fair value of 515.53 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of BDRX and what does it mean?
BDRX has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for BDRX?
515.53 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Biodexa Pharmaceuticals Plc report earnings next?
No upcoming earnings date is recorded for BDRX in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does BDRX have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on BDRX, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.